On August 28, 2014, Chen, Wei; Yan, Shunqi; Loury, David J.; Frye, Leah Lynn; Greenwood, Jeremy Robert; Shelley, Mee Yoo; Wang, Longcheng published a patent.Product Details of 16230-24-3 The title of the patent was Preparation of purine compounds as inhibitors of Bruton’s tyrosine kinase. And the patent contained the following:
Disclosed herein are compounds that form covalent bonds with Bruton’s tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk and reversible inhibitors of Btk. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. Title compound I [R1 = (un)substituted heteroalkyl, (C=O)-alkyl, CHO, etc.; R2 = H, halo, CN, NO2, etc.; R3 independently = halo, CN, NO2, OH, etc.; m = 0-2], and their pharmaceutically acceptable solvates, salts, or prodrugs, are prepared Thus, e.g., II was prepared in a multi-step synthesis starting from 2,4-dichloro-5-nitropyrimidine with tert-Bu (3-aminophenyl)carbamate. Compounds of invention were tested Btk in vitro inhibitory activity, e.g., II showed IC50 value of < 100 nM against Btk. The invention compounds are useful for treating autoimmune diseases and cancer. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Product Details of 16230-24-3
The Article related to purine preparation bruton tyrosine kinase inhibitor autoimmune disease cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Product Details of 16230-24-3
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics